XML 21 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues [Abstract]      
Revenue from collaborative arrangements and other contracts, including affiliated entity $ 10,262,268 $ 1,774,758 $ 7,411,220
Operating expenses:      
Research and development 187,650,503 249,240,324 94,245,436
General and administrative 90,185,285 53,752,353 37,247,828
Total operating expenses 277,835,788 302,992,677 131,493,264
Loss from operations (267,573,520) (301,217,919) (124,082,044)
Other income (expense):      
Interest income 4,782,030 3,363,080 3,311,846
Interest expense (1,253,952) (1,936,447) (8,702,450)
Change in fair value of derivative liability 0 0 (75,670,977)
(Loss) gain on investment in affiliated entities (1,899,654) (553,570) 36,556,658
Net unrealized (loss) gain on available-for-sale equity securities (7,846,172) (3,222,838) 1,695,497
Other (expense) income, net (3,861,584) 343,371 (704,896)
Gain on deconsolidation of Geneos 0 0 4,121,075
Net loss before share in net loss of Geneos (277,652,852) (303,224,323) (162,890,304)
Share in net loss of Geneos (2,165,213) (434,387) (4,584,610)
Net loss (279,818,065) (303,658,710) (167,474,914)
Net loss attributable to non-controlling interest 0 0 1,063,757
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (279,818,065) $ (303,658,710) $ (166,411,157)
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders      
Basic (in dollars per share) $ (1.17) $ (1.45) $ (1.07)
Diluted (in dollars per share) $ (1.17) $ (1.45) $ (1.07)
Weighted average number of common shares outstanding      
Basic (in shares) 238,622,188 208,829,801 155,126,857
Diluted (in shares) 238,622,188 208,829,801 155,126,857
Convertible Bonds      
Other income (expense):      
Gain (loss) on extinguishment of convertible bonds and senior notes $ 0 $ 0 $ (8,177,043)
6.50% Convertible Senior Notes Due 2024      
Other income (expense):      
Gain (loss) on extinguishment of convertible bonds and senior notes $ 0 $ 0 $ 8,762,030